CA2333923A1 - Traitement de la maladie coeliaque a l'aide d'antagonistes de l'interleukine-15 - Google Patents

Traitement de la maladie coeliaque a l'aide d'antagonistes de l'interleukine-15 Download PDF

Info

Publication number
CA2333923A1
CA2333923A1 CA002333923A CA2333923A CA2333923A1 CA 2333923 A1 CA2333923 A1 CA 2333923A1 CA 002333923 A CA002333923 A CA 002333923A CA 2333923 A CA2333923 A CA 2333923A CA 2333923 A1 CA2333923 A1 CA 2333923A1
Authority
CA
Canada
Prior art keywords
cells
expression
cell
fas
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002333923A
Other languages
English (en)
Inventor
Marco Londei
Sonia Quaratino
Luigi Maiuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2333923A1 publication Critical patent/CA2333923A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne le traitement de maladies inflammatoires de l'intestin, telle que la maladie coeliaque, à l'aide d'antagonistes de l'interleukine-15 (IL-15). De préférence, les antagonistes sont des mutéines de l'IL-15, des anticorps contre l'IL-15 ou des molécules d'IL-15 liées à des groupes chimiques qui interfèrent avec l'aptitude de l'IL-15 à effectuer une transduction de signal via les sous-unités .beta. ou .gamma. du complexe récepteur de l'IL-15, mais qui n'interfèrent pas avec la liaison de l'IL-15 avec l'IL-15R.alpha..
CA002333923A 1998-07-10 1999-07-09 Traitement de la maladie coeliaque a l'aide d'antagonistes de l'interleukine-15 Abandoned CA2333923A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9814892.7 1998-07-10
GBGB9814892.7A GB9814892D0 (en) 1998-07-10 1998-07-10 Treatment of celiac disease
PCT/GB1999/002201 WO2000002582A2 (fr) 1998-07-10 1999-07-09 Traitement de la maladie coeliaque a l'aide d'antagonistes de l'interleukine-15

Publications (1)

Publication Number Publication Date
CA2333923A1 true CA2333923A1 (fr) 2000-01-20

Family

ID=10835232

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002333923A Abandoned CA2333923A1 (fr) 1998-07-10 1999-07-09 Traitement de la maladie coeliaque a l'aide d'antagonistes de l'interleukine-15

Country Status (5)

Country Link
EP (1) EP1096949A2 (fr)
JP (1) JP2002520294A (fr)
CA (1) CA2333923A1 (fr)
GB (1) GB9814892D0 (fr)
WO (1) WO2000002582A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
RS51829B (sr) * 2001-08-23 2012-02-29 Genmab A/S. Ljudska antitela specifična za interleukin 15 (il-15)
CU23093A1 (es) 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
EA015897B1 (ru) * 2003-02-26 2011-12-30 Генмаб А/С Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
WO2005099753A1 (fr) * 2004-04-16 2005-10-27 The Govenors Of The University Of Alberta Anticorps de jaune d'oeuf anti-gluten pour le traitement de la maladie caeliaque
CU23472A1 (es) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
NZ569541A (en) 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
US8282928B2 (en) 2007-05-30 2012-10-09 The Governors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
AU2010282280B2 (en) 2009-08-14 2016-06-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 to increase thymic output and to treat lymphopenia
US20180002417A1 (en) * 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
WO2018041989A1 (fr) * 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de diagnostic et de traitement de la maladie coeliaque réfractaire de type 2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
CA2252557A1 (fr) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center, Inc. Antagonistes de l'interleukine-15

Also Published As

Publication number Publication date
JP2002520294A (ja) 2002-07-09
EP1096949A2 (fr) 2001-05-09
WO2000002582A2 (fr) 2000-01-20
GB9814892D0 (en) 1998-09-09
WO2000002582A3 (fr) 2000-03-16

Similar Documents

Publication Publication Date Title
US7235240B2 (en) Antagonists of interleukin-15
US6168783B1 (en) Antagonists of interleukin-15
RU2711979C2 (ru) Белковый комплекс интерлейкина 15 и его применение
US7803361B2 (en) Therapeutic use of interleukin-2 mutants
US6576232B1 (en) IL13 mutants
CA2194299A1 (fr) Nouvelle cytokine designee lerk-5
US20060104945A1 (en) Enhancement of B cell proliferation by IL-15
JPH11502853A (ja) 血管内皮増殖因子拮抗剤
CA2333923A1 (fr) Traitement de la maladie coeliaque a l'aide d'antagonistes de l'interleukine-15
US6884603B2 (en) Nucleic acids encoding IL13 mutants
US6630576B2 (en) Amino acid substitution mutants of interleukin 13
AU7863900A (en) Il13 mutants
EP0749445A1 (fr) Anticorps de fixant au domaine extracellulaire du recepteur du facteur de croissance des colonies de granulocytes g-csf et procedes de traitement
AU700798B2 (en) Antibodies which bind the G-CSF receptor extracellular domain and methods of treatment
WO2006066463A1 (fr) Mutants de lymphotoxines sélectifs vis-à-vis de récepteurs particuliers
ZA200201201B (en) BAFF receptor (BCMA), an immunoregulatory agent.

Legal Events

Date Code Title Description
FZDE Dead